Moderna stock rises 8.8% after mRNA-1469 Phase 2/3 trial advance

Traders Union
All News
Business & Wealth
Companies
Moderna stock rises 8.8% to $248.63

Highlights

Moderna shares rose 8.8% to $248.63 after mRNA-1469 advanced toward Phase 2/3 trials in the DRC targeting Bundibugyo ebolavirus.
Recent analyst coverage shows 19 out of 92 rate Moderna stock a buy, with a median price target of $125 and 11 recommends selling.
Moderna has a market valuation of $89.82 billion and reported trailing revenue of $2.22 billion, employing 4,700 people in biotechnology.

Moderna announced that mRNA-1469, its investigational mRNA vaccine candidate against Bundibugyo ebolavirus (BDBV), has been recommended to advance into a Phase 2/3 efficacy study in the Democratic Republic of the Congo (DRC). The recommendation is supported by encouraging preclinical and Phase 1 data. According to GuruFocus, the World Health Organization recommended the move after reviewing the candidate's data.

View post on X Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Daily uptrend holds as stock gaps higher on renewed optimism

Moderna stock started the session with a gap up from $228.44 to $235.49, setting a bullish tone for the day. The price has held above key moving averages—the MA-20, MA-50, and MA-200—which supports a continuation of the prevailing daily uptrend. The nearest support sits at the prior weekly high of $235.5, helping to reinforce a bullish chart structure.

Odds favor further gains as traders eye a close above range

Traders will be watching for a close above the recent range to gauge whether the shift is being absorbed into the price. The stock opened significantly higher, moving from a previous close of $228.44 to $235.49 at the open, reflecting buyer interest early in the session. Despite a sustained move higher with a firm trend over the past week, the probability of further upside stands at more than 80% for the coming trading week, while the downside probability remains below 20%, with expectations set for a possible trading range between $239.9 and $257.35. Even so, a drop below $235.5 would indicate the advance is losing traction, while the longer-term weekly chart remains constructive.

Previously it was reported that Moderna maintained a bullish technical outlook following strong Phase 3 data for its personalized mRNA cancer vaccine. The advance of mRNA-1469 into late-stage trials adds depth to Moderna’s pipeline momentum, making $235.5 a key support level for traders monitoring potential continuation of the current uptrend.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.